Submission of an abbreviated Biologics License Application("aBLA"), under the Biosimilar Price Competition and Innovation Act of 2009 ("BPCIA"), for a biosimilar version of an already-approved biologic drug constitutes an "artifical act of infringement" for which the biologic's patent owner may file suit. Read more
Friday, October 1 2021 \ Published by Kluwer Patent Blog.
